Axsome Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-191.64	-183.17	-287.22	-239.24	-187.13	-130.4
Depreciation & Amortization	9.94	9.06	7.96	6.83	4.4	0.08
Stock-Based Compensation	96.42	93.75	85.22	62.62	37.73	20.8
Other Adjustments	5.43	9.48	31.73	53.1	4.83	0.97
Change in Receivables	-78.63	-82.46	-47.18	-57.12	-37.7	-
Changes in Inventories	-17.63	-10.66	0.74	-8.16	-1.33	-
Changes in Accounts Payable	-12.66	-6.46	31.32	2.07	25.46	-0.36
Changes in Accrued Expenses	125.26	83.74	56.07	36.45	43.92	0.58
Changes in Other Operating Activities	-7.73	-6.68	-7.05	-1.64	-6.68	0.1
Operating Cash Flow	-71.26	-93.41	-128.41	-145.08	-116.51	-108.23
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-0.7	-0.48	-0.27	-0.58	-0.7	-0.31
Cash Acquisitions	-	-	-	-	-53	-
Investing Cash Flow	-0.7	-0.48	-0.27	-0.58	-53.7	-0.31
Long-Term Debt Issued	280	330	-	85	45	-
Long-Term Debt Repaid	-280	-331.99	-	-	-	-
Net Long-Term Debt Issued (Repaid)	-	-1.99	-	85	45	-
Issuance of Common Stock	118.25	127.46	71.46	271.17	250.01	11.84
Repurchase of Common Stock	-14.02	-7.11	-3.95	-1.84	-0.53	-0.18
Net Common Stock Issued (Repurchased)	104.23	120.35	67.51	269.33	249.48	11.66
Other Financing Activities	-15.44	-16.9	-9.67	-23.32	-9.9	-0.53
Financing Cash Flow	88.79	101.47	57.84	331.01	284.58	11.13
Net Cash Flow	16.83	7.58	-70.84	185.35	114.37	-97.4
Free Cash Flow	-71.96	-93.89	-128.68	-145.66	-117.21	-108.53
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-9.27%	-14.70%	-33.36%	-53.83%	-234.25%	-
Free Cash Flow Per Share	-1.41	-1.89	-2.69	-3.21	-2.88	-2.89
Levered Free Cash Flow	-95.17	-116.64	-198.45	-119.26	-77.07	-130.31
Unlevered Free Cash Flow	-90.14	-97.76	-191.88	-197.78	-114.73	-124.62

SEC Filings: 10-K · 10-Q